Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2139413 | Leukemia Research | 2007 | 4 Pages |
Abstract
Dasatinib is efficient in vitro against most of CML cells harboring ABL kinase domain mutations and induces high rates of response in imatinib-resistant CML patients. Here, we monitored the mutated BCR-ABL transcripts during the follow-up of 12 CML patients treated with dasatinib. We identified four groups of patients based on their sensitivity to dasatinib. Clinical responses were correlated to the in vitro sensitivity of BCR-ABL mutants to dasatinib, however, some discrepancies were observed in a subfraction of CML patients, suggesting subtle differences between in vitro observations and clinical entities and/or the onset of other mechanisms responsible for dasatinib resistance.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Franck E. Nicolini, Kaddour Chabane, Isabelle Tigaud, Mauricette Michallet, Jean-Pierre Magaud, Sandrine Hayette,